2024 will be a critical year for the rare disease community – with crucial policy challenges and opportunities, a competitive election cycle, and continued economic uncertainty, it is now more important than ever for the RDCC to be a fierce advocate for rare disease innovation and access.
Our 2024 Outlook contains ambitious goals to address concerns and opportunities within both pillars, and empowers the RDCC to harness the support and engagement of our member companies and broader rare disease community. With the partnership of champion policymakers, patient advocacy organizations, and key third-party stakeholders, we maintain our commitment to providing hope for the patients living with one of the 95 percent of rare diseases with no FDA-approved treatment.
Read our full outlook below.